Related by context. All words. (Click for frequent words.) 86 Receives Orphan Drug Designation 85 Completes Patient Enrollment 85 Receives Approvable Letter 85 Presents Positive 84 Initiates Phase II 84 Presents Preclinical Data 84 Initiates Clinical 83 Initiates Clinical Trial 83 Licenses Novel 83 Initiates Phase III 83 Reveals Positive 83 Submits Biologics License Application 82 Files IND 82 Earns Milestone Payment 82 Submits NDA 82 Completes Enrollment 82 Receives Fast Track 81 Announce License Agreement 81 Initiates Enrollment 81 Submits Response 81 Receive Milestone Payment 81 Receives Orphan Drug 81 Present Preclinical Data 81 Initiates Dosing 81 Presents Preclinical 80 Begins Dosing 80 Receives Complete Response 80 Reports Preclinical Data 80 Drug Candidate 80 Initiates Clinical Trials 80 Milestone Payment 80 Develop Novel 80 Announce Collaboration Agreement 79 Submits IND 79 Collaborators Publish 79 Phase 2b Clinical Trial 79 Therapeutic Competitors Companies 79 BioSante Pharmaceuticals Announces 79 Achieves Milestone 79 Provides Update Regarding 79 Announces Initiation 79 Receives Notification 79 Announces FDA Clearance 78 Collaborators Present 78 Enrolls First 78 Reports Positive 78 Patient Enrollment 78 Granted Orphan Drug 78 Phase 2a Trial 78 FDA Clears 78 Lupus Drug 78 Successfully Completes Phase 78 Announces Poster Presentations 78 Meets Primary Endpoint 78 Receives Favorable 77 Receives Tentative Approval 77 FDA Accepts 77 Announces Licensing Agreement 77 Awarded Qualifying Therapeutic 77 Extends Collaboration 77 Submits Supplemental 77 Obtains License 77 Drug Fails 77 Announces Positive 77 Presents Positive Preclinical 77 Vaccine Adjuvant 77 Files Shelf Registration Statement 77 Commences Phase 77 Submits Application 77 Drug Shows Promise 77 Demonstrates Significant 77 Cites Positive 77 Sign Licensing Agreement 77 Phase 2b Trial 77 Announce Merger Agreement 77 Gets FDA Clearance 77 Amends Agreement 77 Completes Dosing 77 Jumps Higher 76 Million Milestone Payment 76 Announces Presentation 76 Files Patent Application 76 Systemic Delivery 76 Files Investigational 76 pralatrexate injection folate analogue 76 Lung Cancer Drug 76 Announces License Agreement 76 Settle Patent Litigation 76 JAK2 Inhibitor 76 Sign License Agreement 76 Licenses Patents 76 Phase IIb Clinical Trial 76 Receives Positive Opinion 76 Achieves Primary Endpoint 76 Clinical Trial Results 76 Initiates Phase 76 Sinks Lower 76 Initiates Phase 2b 76 Obtains Exclusive License 76 Announces Tentative Approval 76 Receives Delisting Notification 76 Inc. Nasdaq OXGN 76 Voluntarily Withdraw 76 Receives FDA Clearance 76 IG HCR ;) CO 76 Therapeutic Competitors companiesandmarkets.com adEgemonye 76 Antibody Drug Conjugate 76 Expand Collaboration 76 Inc Therapeutic Competitors 76 Novel Oral 76 IND Filing 76 Patent Covering 76 Announce Licensing Agreement 75 Q2 Loss Narrows 75 FDA Okays 75 Q3 Loss Narrows 75 Successfully Completes Tender Offer 75 Merck OSI Pharmaceuticals 75 Receives Delisting Notice 75 Fast Track Status 75 Oral Calcitonin 75 Arthritis Drug 75 Epilepsy Drug 75 Investigational Compound 75 Announces Publication 75 Reports Receipt 75 Preclinical Data 75 Investigational Treatment 75 Q2 Loss Widens 75 Reacquires 75 Q4 Loss Narrows 75 R MSCRAMM 75 Migraine Drug 75 Restructures Operations 75 Phase III Clinical Trial 75 Q3 Loss Widens 75 Board Authorizes 75 Receives NASDAQ 75 Receives CE Marking 75 Secures Financing 75 Board Unanimously Rejects 75 Announce Initiation 75 Immunomedics Announces 75 Psoriasis Drug 75 Identifies Potential 75 Receives Positive 74 Announces Dosing 74 Receives Funding 74 Settle Patent Dispute 74 Signs License Agreement 74 Shareholders Approve Acquisition 74 Exercises Option 74 Receives Patent 74 Receives Anticipated 74 Acquires Exclusive 74 Begins Shipment 74 Milestone Payments 74 RNAi Therapeutics 74 Phase III Trial 74 Therapeutic Antibody 74 Q1 Loss Narrows 74 Completes Tender Offer 74 Novel Antibiotic 74 Receives Approvals 74 Prostate Cancer Vaccine 74 Small Molecule 74 Initiate Phase III 74 Strengthens Balance Sheet 74 Phase 1b Clinical Trial 74 AUDIO PROVIDED BY 74 Phase IIb Trial 74 Settles Litigation 74 Osteoporosis Drug 74 Pharma Merck Serono 74 Extend Collaboration 74 Terminate Merger Agreement 74 Regains NASDAQ 74 Invites Investors 74 Q1 Loss Widens 74 NDA Submission 74 Announces Discontinuation 74 Nasdaq MNKD focuses 74 Regains Full 74 Announces Favorable 74 Nasdaq XTLB 74 Webcast Presentations 74 Genentech sanofi aventis 74 Abstract Accepted 74 Receives Confirmation 74 Rheumatoid Arthritis Drug 74 TRACON Pharmaceuticals 74 Awarded Patents 74 Q4 Loss Widens 74 Taro Receives 74 Extends Tender Offer 73 Taglich Brothers Initiates Coverage 73 Successfully Concludes 73 Inc. www.micromet inc.com 73 Flamel Technologies Announces 73 Receives Unsolicited 73 Shows Promise 73 Enters Into Licensing Agreement 73 Monoclonal Antibody 73 Single Dose 73 Receives Favorable Ruling 73 Net Loss Narrows 73 FDA Approvals 73 Announce Collaboration 73 Improves Survival 73 Demonstrates Positive 73 Initiate Clinical Trial 73 lead molecular radiotherapeutic 73 Receives Notice 73 Xcytrin R 73 Prolongs Survival 73 Enters Into Collaboration 73 platform HDL Mimetic 73 Gout Drug 73 Milestone Payment From 73 visit http:/www.mannkindcorp.com 73 Announces Successful Completion 73 please visit http:/www.vandapharma.com 73 PRN FDA Approves 73 Explore Strategic Alternatives 73 Key Milestones 73 TM Aganocide 73 Significantly Improves 73 Therapeutic Competitors Report 73 Namenda Memantine HCl 73 Receives SFDA Approval 73 please visit http:/www.supergen.com 73 Launches Generic Version 73 RNAi Therapeutic 73 Posts Wider Loss 73 First Patient Enrolled 73 Initiate Phase 73 Teva Provides Update 73 Kinase Inhibitor 73 Schizophrenia Drug 73 VIVUS Announces 73 CysDisplay R 73 Study Evaluating 73 Novartis Novo Nordisk 73 Mylan Receives Approval 73 Signs Merger Agreement 73 Signs Licensing Agreement 73 Confirms Receipt 73 Preclinical Study 73 Demonstrates Ability 73 Biomarker Study 72 Patients Suffering 72 Stockholders Approve Acquisition 72 Net Loss Widens 72 Achieves Significant 72 Boehringer Ingelheim MedImmune 72 Settles Patent Dispute 72 Receives Tentative FDA 72 Welcomes Analyst Initiation 72 Genentech Wyeth Pharmaceuticals 72 Receives Conditional 72 please visit http:/www.atherogenics.com 72 Receives Clearance 72 Stockholders Approve Merger 72 Phase IIa Clinical Trial 72 Alnylam Nasdaq ALNY 72 Provides Shareholder 72 Patients Treated With 72 Shows Promising 72 Exclusive License 72 Merck Serono Nycomed 72 Paris IPN Euronext 72 Patent Issued 72 Demonstrates Sustained 72 Announces Stockholder Approval 72 Nasdaq AVNC 72 Completes Transaction 72 Genentech GlaxoSmithKline 72 Issued Patent 72 developing ACAPODENE 72 Updates Guidance 72 Announce Licensing 72 Commercialize Novel 72 Secures Funding 72 Receives Commitment 72 Seeks Approval 72 Completes Financing 72 product platforms AZX# 72 Closes Merger 72 Submits Investigational 72 Completes Merger With 72 Nicotine Vaccine 72 Shows Promise Against 72 Antitumor Activity 72 Announces Postponement 72 Phase 2a Clinical Trial 72 Pending Acquisition 72 Strengthens Position 72 Molecular Diagnostic Test 72 Finalizes Purchase 72 NewsBite Downgrade Puts Pressure 72 Receives Subpoena 72 First Patient Treated 72 Commence Phase 72 Investigational Oral 72 Announces Cancellation 72 Completes Patient Enrolment 72 Develop Next Generation 72 Receives Deficiency Letter 72 Subsidiary Enters 72 Cholesterol Drug 72 Broadens Its 72 Combination REOLYSIN R 72 FDA Approves 72 Issues Guidance 72 Introduces Novel 72 Announces Divestiture 72 Secures Additional 72 Protease Inhibitor 72 Q2 Adj 71 Announce Commencement 71 Receives Approval 71 programs visit http:/www.bionovo.com 71 Mutually Agree 71 Transdermal Patch 71 Crofelemer budesonide foam 71 Clinical Trial Evaluating 71 Terminates Merger Agreement 71 Announces Effective Date 71 Idenix Novartis 71 Demonstrates Potential 71 Confirms Commitment 71 Restructures Debt 71 Novel Therapeutic 71 AVI BioPharma Announces 71 Updates Status 71 Announces Organizational Changes 71 Announce Early Termination 71 Collaborates With 71 Improves Outcomes 71 Tech DVAX 71 Explores Strategic Alternatives 71 Completes Previously Announced 71 Cholesterol Lowering Drug 71 Ebola Vaccine 71 Recombinant Protein 71 Amend Merger Agreement 71 Receives Notice From 71 Enters Into License Agreement 71 sanofi aventis Bayer Schering 71 Generic Version 71 Receives Regulatory 71 Study Demonstrates 71 HCV Protease Inhibitor 71 OTC BB PVCT 71 Announce Definitive Agreement 71 Blood Pressure Drug 71 Successfully Closes 71 candidates Azedra TM 71 Provides Guidance 71 Q1 Adj 71 Awarded Patent 71 Aztreonam Lysine 71 Pivotal Study 71 Wins Patent Infringement 71 Acquire Controlling Interest 71 Shares Soar 71 Nasdaq EPCT 71 Commences Phase III 71 Earnings Postmortem 71 FOLOTYN ® 71 Inc. NASDAQ SIRT 71 Biogen Genentech 71 Anti Tumor 71 IND Application 71 Bullish Average Crossover 71 Regains Compliance With 71 Daytradersdigest.com 71 Alvine Pharmaceuticals 71 Files Provisional 71 Closes Previously Announced 71 Cell Transplants 71 Wins Approval 71 Closes Second Tranche 71 Topline Results 71 Recombinant Human 71 Telik logo TELINTRA 71 Announce Expiration 71 Severe Sepsis 71 visit http:/www.PAREXEL.com 71 Trial Evaluating 71 Visit www.BASInc.com 71 FY# Loss Widens 71 Confirms Efficacy 71 Reaffirms Outlook 71 Q4 Profit Surges 71 Significantly Increases 71 Announces Termination 71 Pivotal Phase III 71 Personalized Immunotherapy 71 Unsolicited Proposal From 71 Provides Updates 71 oncolytic virus therapies 71 Expands Portfolio 71 Reconfirms 71 Guides Inline 71 Announces Issuance 71 INDICATED LOWER 71 Expanded Indication 71 Nasdaq ZGEN 71 Myriad logo BRACAnalysis 71 Consummates 71 siRNA Delivery 71 Tibotec BVBA 71 BIOTECHNOLOGY SOURCE 71 Begin Clinical Trials 71 Finalizes Sale Of 71 Accelerate Commercialization 71 Commercializes 71 Obtains Approval 71 Reduces Workforce 71 Obtains Exclusive Rights 71 Announce Settlement 71 Vaccine Protects Against 71 Sangamo BioSciences Announces 71 Announces Dismissal 71 Successfully Completes Acquisition 71 Stays Neutral 71 Develop Innovative 71 Inhaled Insulin 71 Preclinical Models 71 Q4 Profit Soars 71 Patent Infringement Litigation 70 Agonist MABA program 70 Hsp# Inhibitor 70 Q2 Profit Surges 70 Millenium Pharmaceuticals 70 Obtains FDA 70 Completes Recapitalization 70 Buy Privately Held 70 Employment Inducement Awards 70 Initiates Voluntary Recall 70 Announces Favorable Ruling 70 Evaluate Strategic Alternatives 70 visit www.genenews.com 70 Review Strategic Alternatives 70 SIX RO ROG 70 ASE SVA 70 Announce Receipt 70 Has Commenced 70 visit www.sciclone.com 70 Announces Additions 70 Commercialize 70 Identifies Key 70 NASDAQ MNKD focuses 70 Provides Clarification 70 Announces Receipt 70 Bradmer Pharmaceuticals 70 Withdraws Application 70 Spins Out 70 Inc EXEL 70 Generic Versions 70 Reduces Risk 70 Exploring Strategic Alternatives 70 novel MetAP 2 70 4Q Loss Widens 70 Completes Reorganization 70 Expands Scope 70 Immunotherapeutic 70 Files Shelf Registration 70 Reveals Receipt 70 Successfully Treated 70 Anticancer Agent 70 Voluntarily Withdraws 70 please visit www.dyax.com 70 Complete Merger 70 Announces Adjournment 70 Cephalon GlaxoSmithKline 70 Begins Clinical Trial 70 Advanced Melanoma 70 Nasdaq MNKD focused 70 FDA Approves Generic 70 developing ostarine selective 70 VentiRx Pharmaceuticals 70 Receives Accreditation 70 Restate Financial 70 Colaris Colaris AP 70 CFO Resigns 70 MBRX 70 NASDAQ XTLB 70 Antisense Drug 70 Announces Spin Off 70 Expands Scientific Advisory 70 Provides Preliminary 70 Orally Active 70 PPD Declares 70 Announces Definitive Agreement 70 Sign Definitive Merger 70 Vitrasert R 70 estrogen receptor beta agonist 70 Develops Novel 70 Finalizes Acquisition 70 Discontinues 70 Posts Wider 70 Bullish Speculation 70 molecular therapeutics immunotherapies 70 NASDAQ ENMD 70 Tezampanel 70 Announces Recapitalization 70 Successful Completion 70 Completes Initial 70 Jointly Announce 70 Confirmatory Phase 70 Announces Commencement 70 Nasal Powder 70 Receives Certification 70 Inc. Nasdaq IMGN 70 Nasdaq PGNX 70 Backs FY# Outlook 70 Gets Favorable 70 Significantly Reduces 70 Bullish Technical Alert 70 Reduces Debt 70 Antigen Specific 70 please visit http:/www.sunesis.com 70 Tumor Targeting 70 Updates Shareholders 70 STERIS Corporation Announces 70 Hematological Malignancies 70 Ups Guidance 70 Q1 Profit Surges 70 Announces Rebranding 70 microRNA Therapeutics 70 Bearish Speculation 70 Oncology Compounds 70 Nasdaq CTIC 70 Vertex Pharmaceuticals Announces 70 First Patient Dosed 70 Broadens Scope 70 DARA logo 70 Announces Share Repurchase 70 Syntonix Pharmaceuticals 70 Receives Shareholder Approval 70 Achieves Positive 70 Anti Tumor Activity 70 Calls Purchased 70 Receives Regulatory Approvals 70 Nasdaq IMGN 70 Therapeutic Competitors 70 Novartis Organon 70 Increases Ownership 70 Valortim TM 70 Regains Compliance 70 Previously Treated 70 Re Affirms 70 Potent Antiviral Activity 70 Aeolus Pharmaceuticals Announces 70 Completes Expansion 70 Post Earnings Checkup 70 Successfully Completed 70 Pharmacyclics Announces 70 Files Patent 70 Canaccord Genuity Maintains Hold 70 Puts Sold 70 Hold Fourth Quarter 70 Completes Asset 70 Data Suggest 70 Receives Notice Regarding 70 Lowers Guidance 70 Reaffirms FY# Outlook 70 Signs Option Agreement 70 novel proprietary KL4 70 Inflammatory Disease 70 Files Patents 70 Closes Financing 70 JAK Inhibitor 70 Shareholders Approve Merger 70 Settles Patent Litigation 70 Miraculins Announces 70 Genotyping Test 69 Q3 Adj 69 Transcept Pharmaceuticals 69 4SC AG ISIN DE# 69 GTC NASDAQ GTCB 69 By JAMAAL ABDUL 69 Terminates Agreement 69 Nasdaq HALO 69 Gets Approval 69 Malaria Vaccine 69 Retains CCG Investor Relations 69 ExxonMobil Fluor 69 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 69 markets Testim ® 69 Restate Financials 69 Achieves Milestones 69 Corp. NASDAQ CYTR 69 please visit www.eisai.com 69 Aradigm Logo 69 Posts Wider 4Q Loss 69 please visit www.medicinova.com 69 Completes Buyout 69 Unveils Expanded 69 Shows Efficacy 69 Antibody Discovery 69 Achieves Record Sales 69 candidates Azedra 69 Analyst Upgrade 69 Files Annual Report 69 Pruvel TM 69 pharmacogenomic translational research 69 Posts Narrower Loss 69 Adjunctive Therapy 69 Upcoming Deadline 69 Receives Conditional Approval 69 affiliate Evogene Ltd. TASE 69 Announces Underwriters Exercise 69 Attracting Bullish Investors 69 HuCAL PLATINUM R 69 Study Showed 69 Bearish Average Crossover 69 Exploit collaboration 69 Completes Acquisitions 69 Announces Consummation 69 FDA Panel Recommends 69 Potelligent Technology 69 Inflammatory Arthritis 69 Survival Benefit 69 technology visit http:/www.genmab.com 69 1Q Loss Widens 69 Receives Stockholder Approval 69 Hematology Molecular Pathology 69 Spectrum Pharmaceuticals Announces 69 Anti CD# Antibody 69 Successfully Treats 69 Revises Guidance 69 Kosan dependence 69 Grants Orphan Drug 69 Positive Results 69 Ridaforolimus 69 Gets Bearish Confirmation 69 Executes Agreement 69 Stock Soars 69 Rotavirus Vaccine 69 non nucleoside inhibitor 69 Multiple Ascending Dose 69 Seasonal Influenza Vaccine 69 DOR BioPharma Announces 69 Shareholders Approve Merger Agreement 69 Partnering Agreements 69 3Q Loss Widens 69 Loss Shrinks 69 FY# Loss Narrows 69 developing adecatumumab 69 Announcement acc 69 TSX Delisting Review 69 Beats Raises Guidance 69 Receives Authorization 69 Provides Updated 69 Anticancer Drug 69 Adjuvant Treatment 69 Humanized Anti 69 novel emulsion formulation 69 Anticancer Compound 69 Randomized Phase II 69 http:/www.pharmacopeia.com 69 Makes Unsolicited Bid 69 Catalyst Biosciences 69 Recommends Approval 69 markets HP Acthar 69 Nanophase Announces 69 Strengthens Leadership 69 Phase III Pivotal 69 OTCBB FCSC 69 Novel Compounds 69 Supplemental Biologics License Application 69 Subsidiary Receives 69 Announces Ticker Symbol 69 Therapeutic Vaccines 69 Announces Early Termination 69 Boosts Guidance 69 TRANSDUR ® 69 Nasdaq Deficiency Notice 69 euro adhoc Intercell AG 69 Nasdaq Delisting Notice 69 Naglazyme R 69 Tomorrow Cures 69 subsidiaries visit http:/www.apricusbio.com 69 Signs Agreements 69 Extends Offer 69 Pivotal Phase 69 Novel Vaccine 69 Oral Fingolimod 69 Bearish MACD 69 Expand Relationship 69 Announces Stock Repurchase 69 HER2 Positive 69 Q3 Profit Surges 69 Q4 Profit Plunges 69 VP Exercises Options 69 Treatment Reduces 69 initiated Phase Ib 69 Regeneron Pharma 69 Previously Announced 69 Clinical Trial Data 69 Inc. NASDAQ QLTI 69 International www.iscointl.com 69 Inks Licensing Deal 69 visit www.targanta.com 69 WeissComm Partners +#-#-#-# 69 BayStreet.ca Research Alert 69 Announces Immediate Availability 69 Vicriviroc 69 Unveils Groundbreaking 69 please visit www.middlebrookpharma.com 69 Positive Opinion 69 Approve Merger 69 Pivotal Trial 69 Metabolic Disease 69 Reports Narrower 69 MONSTERSTOX.COM Monsterstox.com 69 Receives Positive Results 69 Q4 Profit Climbs 69 Reports Inducement Grants 69 Shares Plummet 69 Delays Filing 69 Completes Reverse Merger 69 Acquires Controlling Interest 69 Unveils Revolutionary 69 Narrows Guidance 69 Q4 Profit Decreases 69 Puts Purchased 69 Study Validates 69 Finalizes Sale 69 Enters Agreement 69 Ondansetron Orally Disintegrating Tablets 69 Further Strengthens 69 Completes Transition 69 Nasdaq VNDA 69 Blood Thinner 69 visit http:/www.neogenomics.org 69 Anounces 69 Phase III Trials 69 Inks MOU 69 GVAX ® 69 Treatment Naïve 69 Patents Covering 69 Extends Expiration Date 69 Completes Merger 69 Host Webcast 69 Enters Into Strategic 69 Adopts Shareholder Rights 69 Effectively Treats 69 Webcast Annual Meeting 69 Clarifies Status 69 HuMax TAC 69 Investigational Drug 69 includes Dideco CarboMedics 69 Changes Ticker Symbol 69 Bush Embraces Pause 69 Inc AMGN AMGN 69 Testosterone Gel 69 Shares Surge 69 Inc SPPI 69 Lifts FY# Outlook 68 Frankfurt XMP 68 Amends Terms 68 Sweetens Bid 68 Therapeutic Potential 68 Canaccord Genuity Reiterates Buy 68 Bristol Myers Squibb Celgene 68 Quark Biotech 68 Completes Purchase Of 68 TriCo Bancshares Announces 68 Nasdaq TARG 68 novel orally inhaled 68 Rated Speculative Buy 68 NYSE SCR Simcere 68 Proves Effective 68 Files Voluntary 68 Therapeutic Vaccine 68 Announces Stock Buyback 68 Skymark Research Initiates Independent 68 Introduces Breakthrough 68 Remains Neutral 68 Moving Average Crossover Alert 68 REG1 Anticoagulation System 68 Inc. ProMetic www.prometic.com 68 Receives Approval From 68 palonosetron hydrochloride Injection Dacogen 68 Proves Successful 68 pipeline ImmunoGen collaborators 68 Prodarsan R 68 GNSZ 68 Restate Results 68 Trastuzumab DM1 68 Therapeutic Antibodies 68 Helps Predict 68 Mouse Model 68 Revises FY# Outlook 68 TRANSDUR ™ 68 Acquire Assets 68 Mouse Models 68 Announces Departure 68 Expands Relationship With 68 Endures Analyst Downgrade 68 Outlines Strategy 68 submitted supplemental Biologics 68 Introduce Next Generation 68 Delivers Next Generation 68 Completes Private Placement 68 topical antifungal product 68 Patient Enrolment 68 Secures Patent 68 Flagship Product 68 Aethlon Medical Releases 68 Issues Clarification 68 Enters Into Exclusive 68 Receives Notice Related 68 Achieves Certification 68 Enters Into Agreement 68 Achieves ISO #:# Certification [002] 68 VIVITROL ® 68 Genes Involved 68 Attains 68 Cardioxyl Pharmaceuticals 68 ARRY # 68 www.palatin.com 68 pentadentate logo R 68 Completes Refinancing 68 NASDAQ VRUS 68 Inhaled Liposomal Ciprofloxacin 68 Announce Completion 68 Polymerase Inhibitor 68 Strengthens Its 68 OTCBB HNAB 68 Posts 4Q 68 Enzon Pharmaceuticals Inc 68 Patent Lawsuit 68 Stockholders Approve 68 Announces Preliminary 68 Announces Shareholder Approval 68 NASDAQ ADLR 68 Medisorb ® 68 II Clinical Trial 68 Announces Repurchase 68 XL# anticancer compounds 68 IPSEN 68 targeted anticancer biopharmaceuticals 68 Vaccine Adjuvants 68 Settle Litigation 68 Underwriters Exercise 68 Maintains Strong 68 Closes Oversubscribed 68 Test Detects 68 Significantly Expands 68 Commence Trading 68 submitted Biologics License 68 J.P. Morgan Healthcare 68 Earnings Scorecard 68 OTCQB CTIX 68 Engages CHF Investor Relations 68 Chronic Hepatitis C 68 SWOT Analysis Aarkstore Enterprise 68 KAI Pharmaceuticals 68 Boosts Buyback 68 Extend Partnership 68 Appoints Seasoned 68 Significantly Improved 68 Gets Clearance 68 Brentuximab Vedotin SGN 68 Q1 Profit Soars 68 Dyax logo 68 Univest Corporation Declares 68 MEDAREX 68 Licensing Pact 68 proprietary capillary aerosolization 68 Completes Restructuring 68 Extends Maturity 68 Files Definitive Proxy 68 Aloxi ® 68 Patients Enrolled 68 Streamlines Operations 68 Orphan Status 68 Ups Bid 68 Inc MEDX 68 Announces Definitive Agreements 68 Adjourns Special Meeting 68 Telik Announces 68 Commences Tender Offer 68 Biodefense Division 68 Acknowledges Receipt 68 Reminds Shareholders 68 Unsolicited Tender Offer 68 Bone Metastases 68 Completes Purchase 68 Joins OTCQX 68 Sign Definitive Agreement 68 FDA Approves Drug 68 website http:/www.celsion.com 68 Pandemic Flu Vaccine 68 S. Arzerra 68 website www.celsion.com 68 FDA APPROVES 68 Inc. Nasdaq MITI 68 Idera Pharmaceuticals 68 Well Tolerated 68 Combination Treatment 68 Secures Long Term 68 OTCBB URGP specialty 68 ATRA IV 68 MorphoSys AG FSE MOR 68 developing Zerenex ferric 68 Completes Divestiture 68 Protein Synthesis 68 Successfully Tested 68 Shown Effective 68 Reaffirms Guidance 68 TB Vaccine 68 Enters Oversold Territory 68 Gene Therapy Trial 68 www.ucb.com 68 Resubmits 68 website http:/www.sinovac.com 68 Study Shows Benefits 68 Nicotine Conjugate Vaccine 68 Weight Loss Drug 68 Takeda Kyowa Hakko Kirin 68 Reports Significantly Improved 68 Novel Mechanism 68 Drug Maker 68 Geokinetics Announces 68 Seek Shareholder Approval 68 RealPennies.com RealPennies.com 68 Drug Combo 68 GlaxoSmithKline MedImmune 68 Declares Qtr 68 Debuts Next Generation 68 Demonstrates Efficacy 68 Smallpox Vaccine 68 Narrows 4Q Loss 68 Pharmaceuticals Initiates 68 Terminates Contract 68 Q4 Profit Declines 68 Corp. www.anavex.com 68 telomerase therapeutic 68 Avian Influenza Vaccine 68 Q1 Profit Decreases 68 Announce Successful Completion 68 Nasdaq CYTX 68 Earns Certification 68 Pooled Analysis 68 Treatment Shows Promise 68 Unveils Breakthrough 68 Vitamin D analogue 68 Staphylococcus aureus Immune Globulin 68 Summarizes 68 Submits Bid 68 Finalizes Agreement 68 Bearish Pressure Building 68 Biologics Manufacturing 68 Initiating Coverage 68 Adopts Stockholder Rights 68 Inks Pact 68 Proven Effective 68 Stem Cell Treatment 68 5 lipoxygenase activating 68 Finalize Agreement 68 AllPennyStocks.com Spotlights 68 Patient Treated 68 Sanofi Aventis Schering Plough 68 Projected Release Date 68 Receives Recognition 68 Gets Subpoena 68 Posts 2Q 68 Onyx Pharmaceuticals Announces 68 Momenta Pharmaceuticals MNTA 68 Demonstrates Potent 68 NMT Medical Announces 68 Anemia Drug 68 Novel Antibody 68 Shows Statistically Significant 68 Metastatic Melanoma 68 Corp. AMEX CVM 68 GENR 68 Appoints Experienced 68 Files Patent Infringement 68 Cancer Stem Cells 68 Q3 Profit Soars 68 Phase 2a Study 68 OTCBB IGXT 68 Webcast Presentation 68 TELINTRA R 68 Inks Licensing Agreement 68 Settles Dispute 68 ENSL 68 developing Bicifadine serotonin 68 CE marked PROGENSA 68 Put Volume Surges 68 Sunesis Pharma 68 Generic Protonix